Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICIs) are promising agents for unresectable hepatocellular carcinoma (uHCC), but lack effective biomarker to predict outcomes. The gut microbiome can modulate tumor response to immunotherapy, but its effect on HCC remains unclear. METHODS: From May 2018 to F...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Pei-Chang, Wu, Chi-Jung, Hung, Ya-Wen, Lee, Chieh Ju, Chi, Chen-Ta, Lee, I-Cheng, Yu-Lun, Kuo, Chou, Shih-Hsuan, Luo, Jiing-Chyuan, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226985/
https://www.ncbi.nlm.nih.gov/pubmed/35738801
http://dx.doi.org/10.1136/jitc-2022-004779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226985/
https://www.ncbi.nlm.nih.gov/pubmed/35738801
http://dx.doi.org/10.1136/jitc-2022-004779

Ejemplares similares